IndieBio

Prellis Biologics, Inc. is a biotechnology company based in San Francisco, California, that specializes in bioprinting human tissues for drug development and organ transplantation. Founded in 2016, the company focuses on overcoming the challenges of creating vascularized human tissues and organs, aiming to revolutionize healthcare. Its innovative technology allows for the precise engineering of human tissues, including lymph node organoids, which can replicate human immune responses for various applications such as antibody discovery and tumor-immune modeling. Prellis Biologics offers a range of products, including TissueWorkshop, Organoids, Vascular Bundles, Tissue Chips, and Holograph X, which collectively enhance early-stage drug discovery and translational pharmacology.

Prellis Biologics, Inc. is a biotechnology company based in San Francisco, California, that specializes in bioprinting human tissues for drug development and organ transplantation. Founded in 2016, the company focuses on overcoming the challenges of creating vascularized human tissues and organs, aiming to revolutionize healthcare. Its innovative technology allows for the precise engineering of human tissues, including lymph node organoids, which can replicate human immune responses for various applications such as antibody discovery and tumor-immune modeling. Prellis Biologics offers a range of products, including TissueWorkshop, Organoids, Vascular Bundles, Tissue Chips, and Holograph X, which collectively enhance early-stage drug discovery and translational pharmacology.

MAA'VA is focused on creating next-generation green building materials that serve as functional alternatives to traditional concrete. The company incorporates recycled plastics, carbon sequestration techniques, and the upcycling of manufacturing waste into its products. By addressing critical issues such as the shortage of river sand, water scarcity, climate change, and waste management, MAA'VA aims to promote sustainable construction practices. Its materials are designed for use in both conventional construction and 3D printing applications, thereby enabling clients to adopt eco-friendly options for their building needs.

BioSapien is a pre-clinical biotechnology company focused on developing innovative biodegradable implantable products for targeted drug delivery in oncology. The company is creating a 3D-printed drug delivery platform known as MediChip, which is designed to administer active pharmaceutical ingredients in a localized and sustained manner. This technology aims to reduce systemic side effects associated with high-dose systemic therapies by delivering drugs directly to cancerous tumor sites. Currently, BioSapien's applications are being explored for pancreatic and lung cancers, with plans to expand its pipeline to include other cancer types such as colorectal, breast, and stomach cancers. The biodegradable mesh used in their products allows for effective treatment while improving patients' quality of care and life.

MAA'VA is focused on creating next-generation green building materials that serve as functional alternatives to traditional concrete. The company incorporates recycled plastics, carbon sequestration techniques, and the upcycling of manufacturing waste into its products. By addressing critical issues such as the shortage of river sand, water scarcity, climate change, and waste management, MAA'VA aims to promote sustainable construction practices. Its materials are designed for use in both conventional construction and 3D printing applications, thereby enabling clients to adopt eco-friendly options for their building needs.

Prellis Biologics, Inc. is a biotechnology company based in San Francisco, California, that specializes in bioprinting human tissues for drug development and organ transplantation. Founded in 2016, the company focuses on overcoming the challenges of creating vascularized human tissues and organs, aiming to revolutionize healthcare. Its innovative technology allows for the precise engineering of human tissues, including lymph node organoids, which can replicate human immune responses for various applications such as antibody discovery and tumor-immune modeling. Prellis Biologics offers a range of products, including TissueWorkshop, Organoids, Vascular Bundles, Tissue Chips, and Holograph X, which collectively enhance early-stage drug discovery and translational pharmacology.

Jointechlabs Inc., established in 2012 with headquarters in Brandon, Florida, specializes in developing point-of-care regenerative medicine technologies. The company offers two primary products: MiniTC® for the U.S. market and Mini-Stem System® for international markets. Both are closed-loop disposable medical devices designed to process autologous body fat into injectable fat grafts and stem cells for non-surgical orthopedic and aesthetic procedures in local medical offices. Jointechlabs aims to simplify and enhance access to cell therapies, enabling hospitals and clinics to provide safe, efficient, and superior results at a reduced cost compared to traditional methods.

Prellis Biologics, Inc. is a biotechnology company based in San Francisco, California, that specializes in bioprinting human tissues for drug development and organ transplantation. Founded in 2016, the company focuses on overcoming the challenges of creating vascularized human tissues and organs, aiming to revolutionize healthcare. Its innovative technology allows for the precise engineering of human tissues, including lymph node organoids, which can replicate human immune responses for various applications such as antibody discovery and tumor-immune modeling. Prellis Biologics offers a range of products, including TissueWorkshop, Organoids, Vascular Bundles, Tissue Chips, and Holograph X, which collectively enhance early-stage drug discovery and translational pharmacology.

Prellis Biologics, Inc. is a biotechnology company based in San Francisco, California, that specializes in bioprinting human tissues for drug development and organ transplantation. Founded in 2016, the company focuses on overcoming the challenges of creating vascularized human tissues and organs, aiming to revolutionize healthcare. Its innovative technology allows for the precise engineering of human tissues, including lymph node organoids, which can replicate human immune responses for various applications such as antibody discovery and tumor-immune modeling. Prellis Biologics offers a range of products, including TissueWorkshop, Organoids, Vascular Bundles, Tissue Chips, and Holograph X, which collectively enhance early-stage drug discovery and translational pharmacology.

Jointechlabs Inc., established in 2012 with headquarters in Brandon, Florida, specializes in developing point-of-care regenerative medicine technologies. The company offers two primary products: MiniTC® for the U.S. market and Mini-Stem System® for international markets. Both are closed-loop disposable medical devices designed to process autologous body fat into injectable fat grafts and stem cells for non-surgical orthopedic and aesthetic procedures in local medical offices. Jointechlabs aims to simplify and enhance access to cell therapies, enabling hospitals and clinics to provide safe, efficient, and superior results at a reduced cost compared to traditional methods.

Prellis Biologics, Inc. is a biotechnology company based in San Francisco, California, that specializes in bioprinting human tissues for drug development and organ transplantation. Founded in 2016, the company focuses on overcoming the challenges of creating vascularized human tissues and organs, aiming to revolutionize healthcare. Its innovative technology allows for the precise engineering of human tissues, including lymph node organoids, which can replicate human immune responses for various applications such as antibody discovery and tumor-immune modeling. Prellis Biologics offers a range of products, including TissueWorkshop, Organoids, Vascular Bundles, Tissue Chips, and Holograph X, which collectively enhance early-stage drug discovery and translational pharmacology.

Prellis Biologics, Inc. is a biotechnology company based in San Francisco, California, that specializes in bioprinting human tissues for drug development and organ transplantation. Founded in 2016, the company focuses on overcoming the challenges of creating vascularized human tissues and organs, aiming to revolutionize healthcare. Its innovative technology allows for the precise engineering of human tissues, including lymph node organoids, which can replicate human immune responses for various applications such as antibody discovery and tumor-immune modeling. Prellis Biologics offers a range of products, including TissueWorkshop, Organoids, Vascular Bundles, Tissue Chips, and Holograph X, which collectively enhance early-stage drug discovery and translational pharmacology.

Pembient, Inc. is a biotechnology company based in Seattle, Washington, founded in 2015. The company specializes in producing synthetic rhino horn and elephant ivory using advanced biotechnological methods, including DNA manipulation and 3D printing of keratin. By offering these bio-fabricated products at prices lower than those that drive poaching, Pembient aims to combat the illegal wildlife trade, which is estimated to be a $20 billion black market. The company also manufactures carvable horns for creating durable goods such as jewelry, libation cups, and chopsticks. Through its innovative approach, Pembient seeks to replace the demand for illegal wildlife products with sustainable alternatives, thereby contributing to the conservation of endangered species.